Access

Access to Treatments

NOTE: This page was updated with generic drug information and information on the province of Ontario Drug Access policy change on  October 31, 2013

The Canada Health Act ensures that all Canadians have access to all insured health services such as medically necessary hospital services, inpatient pharmaceuticals (medicines used while ou are hospitalized), and all medically required physician services.  Prescription drugs used by individuals as outpatients such as with CML patients treatments with Tyrosine Kinase Inhibitors (TKI’s) are not paid for by the system.

All drugs marketed and sold in Canada must be reviewed and approved for sale by the Federal Government through Health Canada.  Although it is the federal government that approves medicines, it is the responsibility of each of the provinces to review and approve the use and reimbursement of all medicines.  Depending on the Province you live in you may or may not have access to a certain drug based on how the province independently decides to provide access to it.  One example would be with the newer TKI’s such as Sprycel and Tasigna.  Although these drugs have been approved federally through Health Canada for use as first line therapy for Chronic Phase (CP) CML not all Provinces may provide funding for their use in this indication.  By clicking on the map of Canada below you will find information regarding the coverage to TKI’s for your Province as well as the current situation regarding the availability of generic imatinib mesylate.

Importantly, generic formulations of imatinib mesylate (Gleevec®, Novartis) are now available in Canada and are being marketed by two different manufacturers, TEVA and Apotex.  Please make sure you familiarize yourself with The CML Society of Canada suggested guidelines for patients switching to generic imatinib mesylate, by clicking on this link: Generics Arrive in Canada.

provincial coverage

Click on the map below for information regarding government reimbursement in your province.

yukon British-Colombia Alberta Saskatchewan Manitoba Ontario Quebec Northwest Territories Nunavut Newfoundland and Labrador New Brunswick Nova Scotia Prince Edward Island

Other coverage

  • If you have been prescribed Gleevec or Tasigna and have questions on insurance coverage or how to pay for your treatment, you or your physician can contact CML Alliance through the toll free number: 1-877 CML ALLI or 1-877-265-2554), 24 hours a day, 7 days a week. Or the toll-free fax number: 1-866-731-1681

For a downloadable CML Alliance application:

CML Alliance

For information on accessing Sprycel:

Logo

Information on CML & Sprycel
· A full service telephone support line
· Reimbursement navigation
· Financial assistance for qualifying patients
· Home delivery of Sprycel (if desired)

And more…

To find out more, please contact the program at 1-877-967-6626.


 

Alberta
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Outpatient Cancer Drug Benefit Program
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb Canada
Coverage:
Yes
Type of coverage:
For the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib.
Outpatient Cancer Drug Benefit Program
Tasigna (Nilotinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
May 22nd, 2012 (updated)Coverage Through Alberta Health Services:Alberta Health Services provides coverage for TASIGNA*, as specified in the Outpatient Cancer Drug Benefit Program, to eligible Alberta residents according to the following criteria:As second line alternative for Imatinib resistant or intolerant, or Dasatinib intolerant CML patients.

Prescribing limited to authorized physicians, group 2 drug listing.

Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the Health Professions Act authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

Tasigna 1st line (new patient) is available through a special authorization form until official listing is announced.

Outpatient Cancer Drug Benefit Program

Intron A (interferon)

Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Outpatient Cancer Drug Benefit Program
For more information:
Drug Coverage List for Alberta
Alberta Cancer Board
Provincial Office
Suite 1220
10405 Jasper Avenue
Edmonton , Alberta
T5J 3N4
Tel: (780) 412 6300
Fax: (780) 412 6326
info@cancerboard.ab.ca

British Columbia

 

generic imatinib mesylate – TEVA formulation

Gleevec (imatinib)

Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
BC Cancer Agency coverage
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb
Coverage:
Yes
Type of coverage:
BC Cancer Agency coverage
Sprycel is accessible for patients of CML on a case-by-case basis via the Compassionate Access Program (CAP) and according to the following criteria:
Patients with CML who are resitant or intolerant to imatinib (Gleevec)
Patients with Accelerated phase of CML, who are resistant or intoleratant to imatinib
patients with Intolerance to imatinib and nilotinib (grade 3 or 4 non-hematologic toxicity) for chronic/accelerated phase CML treatment
Note: sequential use between dasatinib and nilotinib for disease progression is not allowed.
Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
BC Cancer Agency coverage
May 22nd, 2012 (updated)Coverage Through The BC Cancer Agency:TASIGNA* is accessible to patients for the treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia (ULKCMLN) according to the following criteria:Patients with chronic phase CML, who are resistant or intolerant to imatinib (GLEEVEC*):No complete hematologic response (CHR) after 3 months of imatinib*Lack of any cytogenetic response after 6 months of imatinib*Lack of major cytogenetic response (MCR/1 log reduction bcr-abl) after 12 months of imatinib*Lack of complete cytogenetic response (CCR/2 log reduction bcr-abl) after 18 months of imatinib*Cytogenetic relapse on imatinib (loss of CCR/less than 2 log or MCR/less than 1 log or any Ph+ increase greater than or equal to 30%)Loss of CHRProgression to accelerated phase CMLPatients with accelerated phase CML, who are resistant to imatinib (GLEEVEC*):No hematologic response (HR) after a minimum of 4 weeks of imatinib*Lack of any cytogenetic response after 6 months of imatinib*Progression with greater than 50% increase in WBC, blast count, platelets or basophils during imatinib therapyProgression from chronic phase to accelerated phase during imatinib therapyPatients with accelerated phase CML, who are intolerant to imatinib, including patients with: greater than or equal to Grade 3 non-hematologic toxicity, not responding to symptomatic treatment or temporary dose reductionGrade 4 hematologic toxicity lasting greater than 7 daysSustained, highly symptomatic Grade 2 non-hematologic toxicity

Patients with intolerance to dasatinib (grade 3 or 4 non-hematologic toxicity)

Note: sequential use between dasatinib and nilotinib for disease progression is not allowed.

The BC Cancer Agency provides coverage for TASIGNA* as per the above protocol via the Compassionate Access Program (CAP). A Compassionate Access Program (CAP) approval is required prior to the initiation of treatment. Please refer to BCCA Compassionate Access Program website

The CAP system is maintained and updated by the CAP Office who can be contacted at 604.877.6000 x 6277.

No First line coverage of TASIGNA* yet – as of May 22,2012

Intron A (interferon)

Company:
Merck Canada
Coverage:
Yes
Type of coverage:
BC Cancer Agency coverage
For more information:
British Columbia Cancer Agency
Regional Centres:
Frazer Valley
Tel: (604) 930 2098
Toll free: 1 800 523 2885
Southern Interior
Tel: (250) 712 3900
Toll free: 1 888 563 7773
Vancouver
Tel: (604) 877 6000
Toll free: 1 800 663 3333
Vancouver Island
Tel: (250) 519 5500
Toll free: 1 800 670 3322

Manitoba

 

generic imatinib mesylate – Apotex formulation

Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status (EDS)
Sprycel (dasatinib)
Company:
Bristol Myers Squibb
Coverage:
Yes
Type of coverage:
Manitoba Pharmacare
Program
Pharmacare
Tel: (204) 786 7141
Toll-free: 1 800 297 8099
or
Provincial Drug Programs
Manitoba Health
300 Carlton Street
Winnipeg, Manitoba
R3B 3M9
Tel: (204) 786 7318
Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
No – Tasigna coverage is currently under review
Type of coverage:
No
Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status (EDS)
For more information :
Manitoba Pharmacare Program
Pharmacare
Tel: (204) 786 7141
Toll-free: 1 800 297 8099
or
Provincial Drug Programs
Manitoba Health
300 Carlton Street
Winnipeg, Manitoba
R3B 3M9
Tel: (204) 786 7318

New Brunswick
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Special Authorization
Special Authorization information:
Special Authorization Unit
New Brunswick Prescription Drug Program
P.O. Box 690
644 Main Street
Moncton, New Brunswick
E1C 8M7
Local Fax: (506) 867 4872
Toll Free Fax: 1 888 455 8322
Toll Free Inquiry Line: 1 800 332 3691
Tel: (506) 444 5295
Fax: (506) 444 4207
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb
Coverage:
Yes
Type of coverage:
Special Authorization
Special Authorization information:
Special Authorization Unit
New Brunswick Prescription Drug Program
P.O. Box 690
644 Main Street
Moncton, New Brunswick
E1C 8M7
Local Fax: (506) 867 4872
Toll Free Fax: 1 888 455 8322
Toll Free Inquiry Line: 1 800 332 3691
Tel: (506) 444 5295
Fax: (506) 444 4207
Tasigna (Nilotinib)
Company:
Novartis Canada
Coverage:
May 22nd, 2012 (updated):Coverage Through The New Brunswick Prescription Drug ProgramTASIGNA* is covered by the New Brunswick Prescription Drug Program according to the following special authorization criteria:For the treatment of chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in adult patients who:are resistant or intolerant to imatinib, or intolerant to dasatinib

Intron A(interferon)

Company:
Merck Canada
Coverage:
Yes
Type of coverage:
New Brunswick Prescription
Drug Program – Plan AEFGVW
For more information:
New Brunswick health program
New Brunswick Prescription Drug Program
Tel: (506) 867 4515
Toll free: 1 800 332 3692

Newfoundland & Labrador
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Special Authorization Drug
Special Authorization Request Form
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb
Coverage:
Yes
Type of coverage:
Special Authorization

CRITERIA

  • Dasatimib monohydrate (Sprycel 20mg, 50mg and 70mg tablet) –
  • For adult patients with chronic phase CML with primary or acquired resistance to imatinib (600mg/day) at doses of 100mg per day or 70mg two times daily.
  • For adult patients with chronic phase CML who progress to accelerated phase on imatinib 800mg per day. Dosing recommendation: 140mg per day
  • For adult patients with chronic phase CML who has blast crisis while on imatinib 800mg per day. Dosing recommendation: 140mg per day
  • For adult patients with CML have intolerance to imatinib or have experienced grade 3 or higher toxicities to imatinib
  • Renewal criteria: Request for renewal must specify how the patient has benefited from therapy and is expected to continue to do so.
  • Duration of initial approval: 1 year
  • Duration of renewal: 1 year

 

Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
May 22nd, 2012 (updated)Newfoundland has listed Tasigna 150 mg for the treatment of 1st line Philadelphia Chromosome positive myeloid leukemia under the Newfoundland Labrador Prescription Drug ProgramEffective date March 21, 2012Tasigna is listed as a special authorization with the following criteria:“for the first line treatment of adult patients with Philadelphia Chromosome positive myeloid leukemia in chronic phase”Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Special Authorization Drug
Special Authorization Request Form
Newfoundland & Labrador Prescription Drug Program
For more information:
Newfoundland & Labrador Health Information Centre
Tel: (709) 757 2409

Northwest Territories
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Limited use benefit administer by Alberta Blue Cross
Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Alberta Blue Cross coverage
For more information :
www.hlthss.gov.nt.ca
Government of the Northwest Territory
Health Care Coverage
Toll free: 1 800 661 0830

Nova Scotia

 

imatinib mesylate – Apotex

imatinib mesylate – TEVA

Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception Status for Drug Assistance for Cancer Patients
Exception Status Drug form
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb
Coverage:
Yes
Type of coverage:
Exception Status for Drug Assistance for Cancer Patients Exception Status Drug Form

 

Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
Coverage Through Nova Scotia Pharmacare:TASIGNA* is covered by Nova Scotia Pharmacare through the Exception Drug Status (EDS) process according to the following criteria:As a single line agent for the treatment of adults with chronic or accelerated phase CML with resistance or intolerance to prior therapy.This would include:Patients with CML in chronic phase who are intolerant to imatinib or dasatinib or bothPatients with CML in chronic phase who are resistant to imatinib 600mg/dayPatients with CML that have progressed to accelerated phase while on imatinibSequential use of dasatinib and nilotinib is not permitted except in the circumstance described above (i.e. intolerance)

Intron A (interferon)

Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Exception Status for Drug Assistance for Cancer Patients
Exception Status Drug form
For information:
Nova Scotia Pharmacare Programs
PO Box 500
Halifax, Nova Scotia
B3J 2S1
Toll free: 1 800 544 6191
Tel: (902) 429 6565
Fax: (902) 468 9402

Nunavut
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
NIHB or Extended Health Benefit program #1
Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
NIHB or Extended Health Benefit program #1
For more information :
Health and Social Services Website
Government of Nunavut
Health Insurance Program
Toll free: 1 800 661 0833

Ontario

Important – please note the following:

Note: The CML Society of Canada continues to advocate for all patients in Canada and recently has been advised in writing by letter and email from the Ministry of Health and Long-Term Care Ontario Public Drug Programs Office of the Executive Officer and Assistant Deputy Minister, Diane McArthur, that CML patients in Ontario will be able to access a third funded oral tyrosine kinase inhibitor (TKI) if they experience serious side effects after the third month on a 2nd TKI therapy and as long as their disease has not progressed.

(* TKIs: Imatinib, Nilotinib, or Dasatinib)  The CML Society of Canada has clarified with the Executive Drug Director that patients being switched from branded Gleevec to generic imatinib mesylate will still be considered as their first drug if in fact branded Gleevec was the patients first drug.  A switch to a generic formulation does not count or mean that a patient will not be able to access other TKI’s.  

imatinib mesylate – Apotex

imatinib mesylate – TEVA

Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Limited use product
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb
Coverage:
Yes
Type of coverage:
Sprycel is covered for CML by the Ontario Drug Benefit/Trillium Drug Program through Exceptional Access Program according to the folowing criteria:
For adult patients with chronic phase CML- recommended dosage is 100mg/day
Tablet sizes approved: 20mg, 50mg, 70mg and 100mg
For CML accelerated or blast phase with demonstrated intolerance or resistance to Imatinib
Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
May 22nd, 2012 (updated)Reimbursement of Tasigna ® under the Exceptional Access Program (EAP):a) Chronic Phase CML:For the treatment of patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). For any such patient, the dosage for which approval is requested is:300 mg twice daily but not exceeding 800 mg/day (this cover both 1st and 2nd Line CML)Initial approval period: 1 yearRenewal criteria: Confirmation from the clinician that the patient has experienced hematologic and/or cytogenic response and is expected to continue to do soRenewal period: 1 yearNote: Ministry will only fund any TWO of the oral Tyrosine Kinase inhibitors (TKIs) * used for chronic phase CML per patient in a lifetime. (* TKIs: imatinib, nilotinib, or dasatinib)Exception: If the patient develops grade 3 or 4 toxicity on one of the above TKI’s within 3 months of initiating therapy, access to a 3rd oral TKI will be allowed for that patientORb) Accelerated Phase CML:For the treatment of patients with accelerated phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) with documented resistance1 or intolerance2 to imatinib therapy. For any such patient, the dosage for which approval is requested is:May not exceed 800 mg/dayDefinitions of resistance and intolerance:1Imatinib resistance is defined as primary or acquired resistance to imatinib at doses of at least 600 mg/day or via mutational analysis report2Intolerance to imatinib (at any dose) is defined as persistent grade 3 or grade 4 toxicity requiring discontinuation of therapyInitial approval period: 1 yearRenewal criteria: Confirmation from the clinician that the patient has experienced hematologic and/or cytogenic response and is expected to continue to do so

Renewal period: 1 year

Exclusion criteria for Tasigna®:

o Nilotinib is not funded for blast phase CML

o Nilotinib is not funded for Ph+ acute lymphocytic leukemia (ALL)

o Combination treatment with any 2 or more of the oral TKIs ( imatinib, nilotinib or dasatinib) will not be funded

o Nilotinib is not funded as a sequential third line therapy in patients who experience primary or acquired resistance (not including mutational resistance) to dasatinib.

Intron A (interferon)

Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Limited use product
For more information :
Ontario Drug Benefit Program
Ministry INFOline
Toll free: 1 866 532 3161 (Ontario only)
TTY: 1 800 387 5559
Hours of operation
8:30am – 5:00pm

Prince Edward Island

 

imatinib mesylate – Apotex page 49

imatinib mesylate – TEVA page 49

Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status (EDS)
EDS request form
Sprycel (dasatinib)
Company:
Bristol Myers Squibb Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status (EDS)
EDS request form
Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
Coverage Through The Prince Edward Island Drug Cost Assistance Program:TASIGNA* is currently under review by the PEI Drug Cost Assistance Program. The PEI Drug Cost Assistance Program has an Exceptional Drug Request mechanism where physicians may request coverage of medications not listed on the Formulary. Each request is reviewed on an individual case basis. The Exceptional Drug Request form can be used to make the request.Requests can be made using the Exceptional Drug Request FormSubmit completed forms by fax to:PEI Drug Cost Assistance ProgramFAX (902) 368-4905
Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Prince Edward Island Drug Formulary
For more information:
Prince Edward Island Health Program
Cancer Assistance Program
Health Services
Tel: (902) 838-0955

Quebec

 

imatinib mesylate – Apotex – French only, please contact The CML Society of Canada if you need help translating it

imatinib mesylate – TEVA  – French only, please contact The CML Society of Canada if you need help translating it

Exception of using the ‘ do not substitute’ by a prescribing physician.  Please follow this link and review section 3.2.13

‘do not substitute’ French only

Gleevec (imatinib)

Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception drug status
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb Canada
Coverage:
Yes
Type of coverage:
Exception drug status
Sprycel is listed on RAMQ’s liste de medicaments d’exception. The criteria for coverage are:
For adults suffering from CML in the chronic or accelerated phase:
– who have not responded to an imatinib treatment (primary or resistance); or
-whose illness has evolved after initially responding to imatinib (secondary resistance);
or
– who have serious intolerance to imatinib
Tasigna (nilotnib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception drug status
May 22nd, 2012 (updated)Indications recognized for the reimbursement of Tasigna (nilotinib)RAMQTasigna 1st line CML: (in effect since February 1, 2012)For the first-line treatment of chronic myeloid leukemia (CML) in chronic phase.Authorizations will be given for a maximum daily dose of 600 mg for a maximum duration of 6 months.To continue treatment, the physician must provide evidence of the patient’s haematological response.Tasigna 2nd line CML:For the treatment of chronic myeloid leukemia (CML) in chronic phase or accelerated phase in adult patients:• With a failure or sub-optimal response to imatinibOr• With a serious intolerance to imatinibAuthorizations will be given for a maximum daily dose of 1,200 mg for a maximum duration of 6 months.To continue treatment, the doctor will need to provide proof of hematologic response

Intron A (interferon)

Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Exception drug status
For more information:
Quebec health program
Régie d’assurance maladie du Québec (RAMQ)
The Health Insurance Infoline
24 hours a day, 7 days a week
Quebec: (418) 646 4636
Montreal: (514) 864 3411
Toll free: 1 800 561 9749
Agents are available during the following hours:
Monday 8:30 a.m. to 4:30
Tuesday 8:30 a.m. to 4:30
Wednesday 10:00 a.m. to 4:30
Thursday 8:30 a.m. to 4:30
Friday 8:30 a.m. to 4:30
By TDD
(telecommunication device for the deaf)
Quebec: (418) 682 3939
Toll free: 1 800 361 3939

Saskatchewan
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status
Sprycel (Dasatinib)
Company:
Bristol Myers Squibb Canada
Coverage:
Yes
Type of coverage:
Exception drug status
Note Sprycel coverage is for intolerance or resistance to Gleevec at 600 mg dose
Tasigna (nilotinib)
Company:
Novartis Canada
Coverage:
May 22nd, 2012 (updated)Coverage Through Saskatchewan Cancer Agency:The Saskatchewan Cancer Agency provides coverage of TASIGNA* for second-line treatment in patients with Chronic Myeloid Leukemia according to specific eligibility criteria:Approved for the following indications:Chronic Myelogenous Leukemia (CML) – Philadephia Chromosome Positive (Ph+)• Second line treatment in patients with chronic phase or accelerated phase Ph+ CML with primary or acquired resistance to first line therapy with Imatinib or who are intolerant to effective doses of Imatinib• Second line alternative in patients previously initiated on second line treatment with Dasatinib, but are experiencing unacceptable toxicity to Dasatinib
Type of coverage:
Exception Drug Status
Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status
For more information:
Saskatchewan Cancer Agency
Saskatchewan Health
Drug Plan (Prescription)
Tel: (306) 787 3420
Toll free: 1 800 667 7581

Yukon
Gleevec (imatinib)
Company:
Novartis Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status
(under chronic disease program or pharmacare program)
Intron A (interferon)
Company:
Merck Canada
Coverage:
Yes
Type of coverage:
Exception Drug Status
(under chronic disease program or pharmacare program)
For more information:
Yukon Health andSocial Services
Government of Yukon
Box 2703
Whitehorse, Yukon
Y1A 2C6
Tel: (867) 667 3673
Toll free: 1 800-661-0408 local 3673 (Yukon only )
Fax: (867) 667 3096
hss@gov.yk.ca

Private insurance

For all private insurance go to CHLIA website to find your insurance company.  Please note that in the province of Quebec depending on what type of private insurer you have through your employment program, your doctor may not be allowed to override a switch to generic imatinib mesylate.  We advise that you review your drug plan policy carefully with regards to the substitution of generic prescription drugs.

Your private insurance will ask for the DIN number of your drug to see if it is covered.

Find the DIN number

Private insurance information

Rejected claim information

Special Access Program

Health Canada, through its Special Access Programme (SAP), allows doctors to gain access to non-marketed drugs that have not yet been approved for sale in Canada.

The Special Access Programme (SAP) provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada.

Facts sheets, forms and guidance documents

Clinical trials

If you are interested to participate in a clinical trial, ask your doctor if there is an appropriate clinical trial for your condition in your region.

If you are aware of clinical trial on CML share it with us.

Comments are closed .